C-type natriuretic peptide regulates endochondral bone growth through p38 MAP kinase-dependent and - Independent pathways

BMC Developmental Biology

Volumn 7, Issue , 2007, Pages

  Agoston, Hanga ^a   Khan, Sameena ^a   James, Claudine G ^a   Gillespie, J Ryan ^a   Serra, Rosa ^b   Stanton, Lee Anne ^a   Beier, Frank ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP DEPENDENT PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NATRIURETIC PEPTIDE RECEPTOR 3; NATRIURETIC PEPTIDE TYPE C; RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; BONE MINERALIZATION; CARTILAGE CELL; CELL ADHESION; CONTROLLED STUDY; EMBRYO; ENCHONDRAL OSSIFICATION; FEEDBACK SYSTEM; FEMALE; GENE CONTROL; GENE IDENTIFICATION; GROWTH PLATE; HYPERTROPHY; INHIBITION KINETICS; MICROARRAY ANALYSIS; MICRODISSECTION; MOUSE; NONHUMAN; ORGAN CULTURE; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TIBIA; UPREGULATION; VALIDATION PROCESS; ANIMAL; BONE DEVELOPMENT; DNA MICROARRAY; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MITOCHONDRION; ORGAN CULTURE TECHNIQUE; PHYSIOLOGY;

ANIMALS; BONE DEVELOPMENT; MICE; MITOCHONDRIA; NATRIURETIC PEPTIDE, C-TYPE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORGAN CULTURE TECHNIQUES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; TIBIA;

EID: 34047199291     PISSN: None     EISSN: 1471213X     Source Type: Journal    
DOI: 10.1186/1471-213X-7-18     Document Type: Article

References (64)

1. Reaching a genetic and molecular understanding of skeletal development. G Karsenty EF Wagner, Dev Cell 2002 2 389 406 11970890 10.1016/S1534-5807(02) 00157-0
2. Bone development. BR Olsen AM Reginato W Wang, Annu Rev Cell Dev Biol 2000 16 191 220 11031235 10.1146/annurev.cellbio.16.1.191
3. MAP kinases in chondrocyte differentiation. LA Stanton TM Underhill F Beier, Dev Biol 2003 263 165 75 14597193 10.1016/S0012-1606(03)00321-X
4. Physiology and pathophysiology of the growth plate. RT Ballock RJ O'Keefe, Birth Defects Res Part C Embryo Today 2003 69 123 43 10.1002/bdrc.10014
5. Systemic and Local Regulation of the Growth Plate. BCJ van der Eerden M Karperien JM Wit, Endocr Rev 2003 24 782 801 14671005 10.1210/er.2002-0033
6. Morphogenesis and dysmorphogenesis of the appendicular skeleton. L Shum CM Coleman Y Hatakeyama RS Tuan, Birth Defects Res Part C Embryo Today 2003 69 102 22 10.1002/bdrc.10012
7. Heritable diseases of the skeleton. Part II: Molecular insights into skeletal development-matrix components and their homeostasis. S Mundlos BR Olsen, Faseb J 1997 11 227 33 9068611
8. Heritable diseases of the skeleton. Part I: Molecular insights into skeletal development-transcription factors and signaling pathways. S Mundlos BR Olsen, Faseb J 1997 11 125 32 9039954
9. The genetic basis for skeletal diseases. E Zelzer BR Olsen, Nature 2003 423 343 8 12748653 10.1038/nature01659
10. Dwarfism and early death in mice lacking C-type natriuretic peptide. H Chusho N Tamura Y Ogawa A Yasoda M Suda T Miyazawa K Nakamura K Nakao T Kurihara Y Komatsu, Proc Natl Acad Sci USA 2001 98 4016 4021 11259675 10.1073/pnas.071389098
11. Significance of C-type natriuretic peptide (CNP) in endochondral ossification: analysis of CNP knockout mice. Y Komatsu H Chusho N Tamura A Yasoda T Miyazawa M Suda M Miura Y Ogawa K Nakao, J Bone Miner Metab 2002 20 331 6 12434160 10.1007/s007740200048
12. Regulation of fetal rat bone growth by C-type natriuretic peptide and cGMP. V Mericq JA Uyeda KM Barnes F De Luca J Baron, Pediatr Res 2000 47 189 93 10674345
13. Natriuretic peptide regulation of endochondral ossification. Evidence for possible roles of the C-type natriuretic peptide/guanylyl cyclase-B pathway. A Yasoda Y Ogawa M Suda N Tamura K Mori Y Sakuma H Chusho K Shiota K Tanaka K Nakao, J Biol Chem 1998 273 11695 700 9565590 10.1074/jbc.273.19.11695
14. Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux. CF Bartels H Bukulmez P Padayatti DK Rhee C van Ravenswaaij-Arts RM Pauli S Mundlos D Chitayat LY Shih LI Al-Gazali, Am J Hum Genet 2004 75 27 34 15146390 10.1086/422013
15. The natriuretic peptidesAn introduction. GF Baxter, Basic Res Cardiol 2004 99 71 5 14963664 10.1007/s00395-004-0457-8
16. Natriuretic Peptides, Their Receptors and cGMP-dependent Signaling Functions. LR Potter S Abbey-Hosch DM Dickey, Endocr Rev 2005
17. C-type natriuretic peptide and guanylyl cyclase B receptor. S Schulz, Peptides 2005 26 1024 34 15911070 10.1016/j.peptides.2004.08.027
18. Natriuretic peptide family: new aspects. LB Cea, Curr Med Chem Cardiovasc Hematol Agents 2005 3 87 98 15853696 10.2174/1568016053544309
19. Intestinal secretory defects and dwarfism in mice lacking cGMP-dependent protein kinase II. A Pfeifer A Aszodi U Seidler P Ruth F Hofmann R Fassler, Science 1996 274 2082 6 8953039 10.1126/science.274.5295.2082
20. Cyclic GMP-dependent protein kinase II plays a critical role in C-type natriuretic peptide-mediated endochondral ossification. T Miyazawa Y Ogawa H Chusho A Yasoda N Tamura Y Komatsu A Pfeifer F Hofmann K Nakao, Endocrinology 2002 143 3604 10 12193576 10.1210/en.2002-220307
21. Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. A Yasoda Y Komatsu H Chusho T Miyazawa A Ozasa M Miura T Kurihara T Rogi S Tanaka M Suda, Nat Med 2004 10 80 86 14702637 10.1038/nm971
22. Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis. P Krejci B Masri V Fontaine PB Mekikian M Weis H Prats WR Wilcox, J Cell Sci 2005 118 5089 5100 16234329 10.1242/jcs.02618
23. Complementary antagonistic actions between C-type natriuretic peptide and the MAPK pathway through FGFR-3 in ATDC5 cells. A Ozasa Y Komatsu A Yasoda M Miura Y Sakuma Y Nakatsuru H Arai N Itoh K Nakao, Bone 2005 36 1056 64 15869918 10.1016/j.bone.2005.03.006
24. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. G Pearson F Robinson T Beers Gibson BE Xu M Karandikar K Berman MH Cobb, Endocr Rev 2001 22 153 83 11294822 10.1210/er.22.2.153
25. MAP kinase pathways. MH Cobb, Prog Biophys Mol Biol 1999 71 479 500 10354710 10.1016/S0079-6107(98)00056-X
26. Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype. S Murakami G Balmes S McKinney Z Zhang D Givol B de Crombrugghe, Genes Dev 2004 18 290 305 14871928 10.1101/gad.1179104
27. Constitutive activation of MKK6 in chondrocytes of transgenic mice inhibits proliferation and delays endochondral bone formation. R Zhang S Murakami F Coustry Y Wang B de Crombrugghe, PNAS 2006 103 365 370 16387856 10.1073/pnas.0507979103
28. Microarray Analyses of Gene Expression during Chondrocyte Differentiation Identifies Novel Regulators of Hypertrophy. CG James CTG Appleton V Ulcii TM Underhill F Beier, Mol Biol Cell 2005 16 5316 5333 16135533 10.1091/mbc.E05-01- 0084
29. Primary murine limb bud mesenchymal cells in long-term culture complete chondrocyte differentiation: TGF-beta delays hypertrophy and PGE2 inhibits terminal differentiation. X Zhang N Ziran JJ Goater EM Schwarz JE Puzas RN Rosier M Zuscik H Drissi RJ O'Keefe, Bone 2004 34 809 17 15121012 10.1016/j.bone.2003.12.026
30. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. X Zhang EM Schwarz DA Young JE Puzas RN Rosier RJ O'Keefe, J Clin Invest 2002 109 1405 15 12045254 10.1172/JCI200215681
31. PGE2 inhibits chondrocyte differentiation through PKA and PKC signaling. TF Li MJ Zuscik AM Ionescu X Zhang RN Rosier EM Schwarz H Drissi RJ O'Keefe, Exp Cell Res 2004 300 159 69 15383323 10.1016/j.yexcr.2004.06.019
32. Osteoclast precursors, RANKL/RANK, and immunology. L Xing EM Schwarz BF Boyce, Immunol Rev 2005 208 19 29 16313338 10.1111/j.0105-2896.2005.00336.x
33. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. PJ Kostenuik, Curr Opin Pharmacol 2005 5 618 25 16188502 10.1016/j.coph.2005.06.005
34. The KEGG database. M Kanehisa, Novartis Found Symp 2002 247 91 101 discussion 101-3, 119-28, 244-52. 12539951
35. Expression profile of genes related to osteoclastogenesis in mouse growth plate and articular cartilage. K Kishimoto R Kitazawa M Kurosaka S Maeda S Kitazawa, Histochem Cell Biol 2005 1 10
36. Detection of osteoprotegerin (OPG) and its ligand (RANKL) mRNA and protein in femur and tibia of the rat. G Silvestrini P Ballanti F Patacchioli M Leopizzi N Gualtieri P Monnazzi E Tremante D Sardella E Bonucci, J Mol Histol 2005 36 59 67 15704000 10.1007/s10735-004-3839-1
37. Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. V Kartsogiannis H Zhou NJ Horwood RJ Thomas DK Hards JM Quinn P Niforas KW Ng TJ Martin MT Gillespie, Bone 1999 25 525 34 10574572 10.1016/S8756-3282(99)00214-8
38. Mitogen-activated protein kinase p38 mediates regulation of chondrocyte differentiation by parathyroid hormone. X Zhen L Wei Q Wu Y Zhang Q Chen, J Biol Chem 2000 275 15
39. Rac1/Cdc42 and RhoA GTPases antagonistically regulate chondrocyte proliferation, hypertrophy, and apoptosis. G Wang F Beier, J Bone Miner Res 2005 20 1022 31 15883643 10.1359/JBMR.050113
40. p38 MAP kinase signalling is required for hypertrophic chondrocyte differentiation. LA Stanton S Sabari AV Sampaio TM Underhill F Beier, Biochem J 2004 378 53 62 14594450 10.1042/BJ20030874
41. Inhibition of p38 MAPK signaling in chondrocyte cultures results in enhanced osteogenic differentiation of perichondral cells. LA Stanton F Beier, Exp Cell Res 2007 313 146 55 17067574 10.1016/j.yexcr.2006.09.027
42. Regulation of cyclooxygenase 2 mRNA stability by the mitogen-activated protein kinase p38 signaling cascade. M Lasa KR Mahtani A Finch G Brewer J Saklatvala AR Clark, Mol Cell Biol 2000 20 4265 74 10825190 10.1128/MCB.20.12. 4265-4274.2000
43. p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. JL Dean M Brook AR Clark J Saklatvala, J Biol Chem 1999 274 264 9 9867839 10.1074/jbc.274.1.264
44. A p38 MAP kinase inhibitor regulates stability of interleukin-1-induced cyclooxygenase-2 mRNA. SH Ridley JL Dean SJ Sarsfield M Brook AR Clark J Saklatvala, FEBS Lett 1998 439 75 80 9849881 10.1016/S0014-5793(98)01342-8
45. Regulation of osteoblast, chondrocyte, and osteoclast functions by fibroblast growth factor (FGF)-18 in comparison with FGF-2 and FGF-10. T Shimoaka T Ogasawara A Yonamine D Chikazu H Kawano K Nakamura N Itoh H Kawaguchi, J Biol Chem 2002 277 7493 500 11741978 10.1074/jbc.M108653200
46. Activation of the ERK1/2 and p38 Mitogen-activated Protein Kinase Pathways Mediates Fibroblast Growth Factor-induced Growth Arrest of Chondrocytes. A Raucci E Laplantine A Mansukhani C Basilico, J Biol Chem 2004 279 1747 1756 14593093 10.1074/jbc.M310384200
47. Regulator of G-protein signaling (RGS) proteins differentially control chondrocyte differentiation. CT Appleton CG James F Beier, J Cell Physiol 2006 16489565
48. The transcription factor ATF3 is upregulated during chondrocyte differentiation and represses cyclin D1 and A gene transcription. CG James A Woods TM Underhill F Beier, BMC Mol Biol 2006 7 30 16984628 10.1186/1471-2199-7- 30
49. Cyclic GMP-dependent protein kinase II is a molecular switch from proliferation to hypertrophic differentiation of chondrocytes. H Chikuda F Kugimiya K Hoshi T Ikeda T Ogasawara T Shimoaka H Kawano S Kamekura A Tsuchida N Yokoi, Genes Dev 2004 18 2418 2429 15466490 10.1101/gad.1224204
50. Cartilage-derived morphogenetic protein-1. FP Luyten, Int J Biochem Cell Biol 1997 29 1241 4 9451821 10.1016/S1357-2725(97)00025-3
51. Mechanisms of GDF-5 action during skeletal development. PH Francis-West A Abdelfattah P Chen C Allen J Parish R Ladher S Allen S MacPherson FP Luyten CW Archer, Development 1999 126 1305 15 10021348
52. Mouse limb deformity mutations disrupt a global control region within the large regulatory landscape required for Gremlin expression. A Zuniga O Michos F Spitz A-PG Haramis L Panman A Galli K Vintersten C Klasen W Mansfield S Kuc, Genes Dev 2004 18 1553 1564 15198975 10.1101/gad.299904
53. Gremlin is the BMP antagonist required for maintenance of Shh and Fgf signals during limb patterning. MK Khokha D Hsu LJ Brunet MS Dionne RM Harland, Nat Genet 2003 34 303 7 12808456 10.1038/ng1178
54. Control of vertebrate limb outgrowth by the proximal factor Meis2 and distal antagonism of BMPs by Gremlin. J Capdevila T Tsukui C Rodriquez Esteban V Zappavigna JC Izpisua Belmonte, Mol Cell 1999 4 839 49 10619030 10.1016/S1097-2765(00)80393-7
55. The BMP antagonist Gremlin regulates outgrowth, chondrogenesis and programmed cell death in the developing limb. R Merino J Rodriguez-Leon D Macias Y Ganan AN Economides JM Hurle, Development 1999 126 5515 22 10556075
56. Signal relay by BMP antagonism controls the SHH/FGF4 feedback loop in vertebrate limb buds. A Zuniga AP Haramis AP McMahon R Zeller, Nature 1999 401 598 602 10524628 10.1038/44157
57. Growth differentiation factor 9 regulates expression of the bone morphogenetic protein antagonist gremlin. SA Pangas CJ Jorgez MM Matzuk, J Biol Chem 2004 279 32281 6 15133038 10.1074/jbc.M403212200
58. Paresis of a bone morphogenetic protein-antagonist response in a genetic disorder of heterotopic skeletogenesis. J Ahn L Serrano de la Pena EM Shore FS Kaplan, J Bone Joint Surg Am 2003 85-A 667 74 12672843
59. Bone morphogenetic proteins induce gremlin, a protein that limits their activity in osteoblasts. RC Pereira AN Economides E Canalis, Endocrinology 2000 141 4558 63 11108268 10.1210/en.141.12.4558
60. Parathyroid hormone-related peptide (PTHrP)-dependent and -independent effects of transforming growth factor beta (TGF-beta) on endochondral bone formation. R Serra A Karaplis P Sohn, J Cell Biol 1999 145 783 94 10330406 10.1083/jcb.145.4.783
61. The perichondrium plays an important role in mediating the effects of TGF-beta1 on endochondral bone formation. J Alvarez J Horton P Sohn R Serra, Dev Dyn 2001 221 311 21 11458391 10.1002/dvdy.1141
62. Distinguishing the contributions of the perichondrium, cartilage, and vascular endothelium to skeletal development. C Colnot C Lu D Hu JA Helms, Dev Biol 2004 269 55 69 15081357 10.1016/j.ydbio.2004.01.011
63. Babelomics. http://babelomics.bioinfo.cipf.es/index.html
64. RhoA/ROCK signaling regulates Sox9 expression and actin organization during chondrogenesis. A Woods G Wang F Beier, J Biol Chem 2005 280 11626 34 15665004 10.1074/jbc.M409158200